Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central anxious procedure, conolidine modulates alternate molecular targets. A Science Improvements study found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, wh